HomeIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
Previous close
$34.10
Day range
$33.15 - $33.77
Year range
$33.15 - $54.44
Market cap
5.28B USD
Avg Volume
1.46M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 133.81M | -7.21% |
Operating expense | 259.28M | -2.73% |
Net income | -140.48M | 4.70% |
Net profit margin | -104.98 | -2.70% |
Earnings per share | -0.72 | 14.35% |
EBITDA | -145.68M | -3.99% |
Effective tax rate | 2.51% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.49B | 11.10% |
Total assets | 3.08B | 5.01% |
Total liabilities | 2.42B | -7.63% |
Total equity | 662.47M | — |
Shares outstanding | 157.90M | — |
Price to book | 8.12 | — |
Return on assets | -12.88% | — |
Return on capital | -15.15% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -140.48M | 4.70% |
Cash from operations | -114.99M | -5.47% |
Cash from investing | -340.80M | -595.98% |
Cash from financing | 496.05M | 1,637.32% |
Net change in cash | 40.61M | 155.84% |
Free cash flow | -46.15M | 46.55% |
About
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Founded
1989
Headquarters
Website
Employees
927
